[go: up one dir, main page]

BR0307994A - Anticorpo monoclonal de antitenascina humana - Google Patents

Anticorpo monoclonal de antitenascina humana

Info

Publication number
BR0307994A
BR0307994A BR0307994-5A BR0307994A BR0307994A BR 0307994 A BR0307994 A BR 0307994A BR 0307994 A BR0307994 A BR 0307994A BR 0307994 A BR0307994 A BR 0307994A
Authority
BR
Brazil
Prior art keywords
monoclonal antibody
human
antitenascin
antitenascin monoclonal
antibody
Prior art date
Application number
BR0307994-5A
Other languages
English (en)
Inventor
Rita De Santis
Anna Maria Anastasi
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of BR0307994A publication Critical patent/BR0307994A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

"ANTICORPO MONOCLONAL DE ANTITENASCINA HUMANA". A presente invenção refere-se a um novo anticorpo monocional ST2146 antitenascina humana dotado de alta afinidade com o antígeno nativo e alta seletividade ao tumor. O hibridoma cST2146 produz de forma estável o anticorpo em condições de cultura de alta densidade e é adequado para o desenvolvimento industrial dos produtos com base no ST2146. O ST2146 exibe propriedades que podem ser exploradas tanto para as aplicações terapêuticas quanto de diagnóstico.
BR0307994-5A 2002-02-26 2003-02-20 Anticorpo monoclonal de antitenascina humana BR0307994A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35929902P 2002-02-26 2002-02-26
PCT/IT2003/000098 WO2003072608A1 (en) 2002-02-26 2003-02-20 Anti-human tenascin monoclonal antibody

Publications (1)

Publication Number Publication Date
BR0307994A true BR0307994A (pt) 2004-12-07

Family

ID=27766061

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307994-5A BR0307994A (pt) 2002-02-26 2003-02-20 Anticorpo monoclonal de antitenascina humana

Country Status (19)

Country Link
US (3) US7438908B2 (pt)
EP (1) EP1478667B1 (pt)
JP (1) JP4488746B2 (pt)
KR (1) KR101048894B1 (pt)
CN (1) CN1317303C (pt)
AR (1) AR038700A1 (pt)
AT (1) ATE480564T1 (pt)
AU (1) AU2003215900B2 (pt)
BR (1) BR0307994A (pt)
CA (1) CA2475395C (pt)
CY (1) CY1111108T1 (pt)
DE (1) DE60334076D1 (pt)
DK (1) DK1478667T3 (pt)
ES (1) ES2352180T3 (pt)
MX (1) MXPA04008216A (pt)
PL (1) PL213216B1 (pt)
PT (1) PT1478667E (pt)
SI (1) SI1478667T1 (pt)
WO (1) WO2003072608A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20040105A1 (it) * 2004-02-27 2004-05-27 Tecnogen Scpa Anticorpo monoclonale antitenascina umana.
EP2057193B1 (en) 2006-08-04 2013-12-18 Novartis AG Ephb3-specific antibody and uses thereof
US10416162B2 (en) 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
FR2930036B1 (fr) * 2008-04-11 2010-05-07 Assist Publ Hopitaux De Paris Procede de diagnostic d'une hypertension arterielle pulmonaire.
US8187601B2 (en) * 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
CA2764386C (en) 2008-12-01 2018-05-01 Laboratory Corporation Of America Holdings P95-her2 antibodies and uses thereof
EP2387711B1 (en) 2009-01-15 2015-04-22 Laboratory Corporation of America Holdings Methods of determining patient response by measurement of her-3
CN102439452B (zh) * 2009-01-15 2015-04-15 美国控股实验室公司 通过测量her-2表达确定患者应答的方法
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
AU2010319531A1 (en) * 2009-11-10 2012-05-24 Amgen Inc. Anti-c-MPL antibodies
AU2011315920B2 (en) 2010-10-15 2016-04-28 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
US8863283B2 (en) 2011-03-31 2014-10-14 Mcafee, Inc. System and method for securing access to system calls
US8813227B2 (en) 2011-03-29 2014-08-19 Mcafee, Inc. System and method for below-operating system regulation and control of self-modifying code
US9262246B2 (en) 2011-03-31 2016-02-16 Mcafee, Inc. System and method for securing memory and storage of an electronic device with a below-operating system security agent
US8925089B2 (en) 2011-03-29 2014-12-30 Mcafee, Inc. System and method for below-operating system modification of malicious code on an electronic device
US8966629B2 (en) 2011-03-31 2015-02-24 Mcafee, Inc. System and method for below-operating system trapping of driver loading and unloading
US9317690B2 (en) 2011-03-28 2016-04-19 Mcafee, Inc. System and method for firmware based anti-malware security
US9032525B2 (en) 2011-03-29 2015-05-12 Mcafee, Inc. System and method for below-operating system trapping of driver filter attachment
US8966624B2 (en) 2011-03-31 2015-02-24 Mcafee, Inc. System and method for securing an input/output path of an application against malware with a below-operating system security agent
US8959638B2 (en) 2011-03-29 2015-02-17 Mcafee, Inc. System and method for below-operating system trapping and securing of interdriver communication
US9087199B2 (en) 2011-03-31 2015-07-21 Mcafee, Inc. System and method for providing a secured operating system execution environment
US9038176B2 (en) 2011-03-31 2015-05-19 Mcafee, Inc. System and method for below-operating system trapping and securing loading of code into memory
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
CN104105967B (zh) * 2011-12-12 2017-03-08 牛津大学科技创新有限公司 生腱蛋白c及其在类风湿关节炎的用途
EP2968503B1 (en) 2013-03-15 2018-08-15 Intrinsic LifeSciences LLC Anti-hepcidin antibodies and uses thereof
GB201414021D0 (en) * 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
WO2016049036A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
GB201602413D0 (en) * 2016-02-10 2016-03-23 Nascient Ltd Method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687732A (en) * 1983-06-10 1987-08-18 Yale University Visualization polymers and their application to diagnostic medicine
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994021293A1 (en) * 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
WO1994028025A1 (en) * 1993-05-28 1994-12-08 The Scripps Research Institute Methods and compositions for inhibiting cd14 mediated cell activation
US6335014B1 (en) * 1998-06-17 2002-01-01 The Institute Of Physical And Chemical Research Medicament for suppressing cancer metastasis
ITRM20020128A1 (it) 2002-03-08 2003-09-08 Sigma Tau Ind Farmaceuti Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting".

Also Published As

Publication number Publication date
CA2475395C (en) 2011-08-02
KR101048894B1 (ko) 2011-07-13
DE60334076D1 (de) 2010-10-21
JP2005534615A (ja) 2005-11-17
CY1111108T1 (el) 2015-06-11
US20040005643A1 (en) 2004-01-08
CA2475395A1 (en) 2003-09-04
EP1478667B1 (en) 2010-09-08
ATE480564T1 (de) 2010-09-15
US20110020219A1 (en) 2011-01-27
PL213216B1 (pl) 2013-01-31
AR038700A1 (es) 2005-01-26
SI1478667T1 (sl) 2010-12-31
DK1478667T3 (da) 2010-12-20
AU2003215900B2 (en) 2008-09-25
PT1478667E (pt) 2010-12-09
US20050106145A1 (en) 2005-05-19
JP4488746B2 (ja) 2010-06-23
CN1317303C (zh) 2007-05-23
CN1639192A (zh) 2005-07-13
ES2352180T3 (es) 2011-02-16
HK1078589A1 (en) 2006-03-17
WO2003072608A1 (en) 2003-09-04
EP1478667A1 (en) 2004-11-24
KR20040086426A (ko) 2004-10-08
AU2003215900A1 (en) 2003-09-09
US7438908B2 (en) 2008-10-21
US8048417B2 (en) 2011-11-01
PL372803A1 (en) 2005-08-08
MXPA04008216A (es) 2004-11-26

Similar Documents

Publication Publication Date Title
BR0307994A (pt) Anticorpo monoclonal de antitenascina humana
Johnson Isolation and characterization of a constitutive form of rabbit liver microsomal cytochrome P-450.
Natali et al. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
DE69737683D1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
TR199902562T2 (xx) De�i�tirilmi� TNF alfa molek�lleri
BR0316101A (pt) Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos
EA200970923A1 (ru) АНТИ-EpСАМ АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ
DE59508864D1 (de) MONOKLONALER ANTIKÖRPER GEGEN CD44v6
EA200501286A1 (ru) МОЛЕКУЛЫ АНТИТЕЛ СО СПЕЦИФИЧНОСТЬЮ К ЧЕЛОВЕЧЕСКОМУ IL-1β
BRPI9915679B8 (pt) composições e métodos para aumentar a mineralização óssea
ATE161582T1 (de) Monoklonale antikörper der maus
NO994983D0 (no) Fremgangsmåte for fremstilling av anti-humane antigenreseptorer, samt anvendelse av disse
BRPI0418766A (pt) anticorpos e moléculas derivadas destes que se ligam às proteìnas steap-1
BRPI0412245A (pt) anticorpos de rg1 e usos destes
ATE373016T1 (de) Induktion von immunologischer toleranz gegen einen therapeutischen antikörper durch varianten des therapeutischen antikörpers
ATE89566T1 (de) Molekuele mit mindestens einer peptidsequenz einer oder mehrerer epitopen eines p.falciparum- produzierten proteins in hepatozyten und zusammensetzungen davon.
BR0113213A (pt) Método para diagnosticar uma doença auto-imune, anticorpo, composição de diagnóstico, e, uso do anticorpo
DE69938725D1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
ATE356223T1 (de) Gen und protein mit bezug zu hepatozellulärem karzinom
ATE442157T1 (de) Verwendung von anti-cd3 monoklonale antikírper und il-5 zur behandlung von autoimmunkrankheiten
DE3884316D1 (de) Synthetische Peptide, gegen diese gerichtete Antikörper und deren Verwendung.
HUP9800613A2 (hu) Humán Fas-antigén elleni humanizált antitest
DE69033810D1 (de) Herstellung und verwendung des menschlichen nm23-h2-proteins und dagegen gerichtete antikörper
ATE160359T1 (de) Antigene regionen von tumorfreigestzten partikeln (tlp) komplexen und antikörper die sie erkennen.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 16/18 (2006.01), C07K 16/30 (2006.01), G01N 3

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2450 DE 19-12-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.